Androgen deprivation therapy did not increase the risk of Alzheimer's and Parkinson's disease in patients with prostate cancer

S. D. Chung, H. C. Lin, M. C. Tsai, L. T. Kao, C. Y. Huang, Kuan Chen Chen

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Androgen deprivation therapy (ADT) has been the standard treatment for advanced prostate cancer for many decades. Although potential adverse effects of ADT have been reported, there are no empirical studies investigating the association between ADT and Alzheimer's disease. Therefore, this retrospective cohort study explored the relationship between the use of ADT and the subsequent risk of Alzheimer's disease in men with prostate cancer using a population-based database. We retrieved data from the "Taiwan Longitudinal Health Insurance Database 2000." The study included 1335 patients with prostate cancer and 4005 age-matched comparison patients without prostate malignancy. We then individually tracked each patient (n = 5340) for a 5-year period to discriminate those who subsequently received a diagnosis of Alzheimer's disease. The Cox proportional hazard regression showed that the hazard ratio (HR) for Alzheimer's disease during the 5-year follow-up period for prostate cancer patients was 1.71 (95% confidence interval (CI) = 0.90~3.25) over that of comparison patients. We further analyzed the hazard ratio for Alzheimer's disease and Parkinson's disease between prostate cancer patients who did and those who did not receive ADT, but we failed to observe a significant difference in the hazard ratio for both diseases during the 5-year follow-up period (adjusted HR = 1.76, 95% CI = 0.55~5.62, and HR = 1.13, 95% CI = 0.58~2.20, respectively). In conclusion, this study demonstrated that the use of androgen deprivation therapy in patients with prostate cancer was not associated with a higher risk of Alzheimer's and Parkinson's disease during the follow-up period.

Original languageEnglish
Pages (from-to)481-485
Number of pages5
JournalAndrology
Volume4
Issue number3
DOIs
Publication statusPublished - May 1 2016

Fingerprint

Androgens
Parkinson Disease
Prostatic Neoplasms
Alzheimer Disease
Confidence Intervals
Therapeutics
Databases
Health Insurance
Taiwan
Prostate
Cohort Studies
Retrospective Studies
Population
Neoplasms

Keywords

  • Alzheimer's disease
  • Androgen deprivation therapy
  • Prostate cancer

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Reproductive Medicine
  • Urology

Cite this

Androgen deprivation therapy did not increase the risk of Alzheimer's and Parkinson's disease in patients with prostate cancer. / Chung, S. D.; Lin, H. C.; Tsai, M. C.; Kao, L. T.; Huang, C. Y.; Chen, Kuan Chen.

In: Andrology, Vol. 4, No. 3, 01.05.2016, p. 481-485.

Research output: Contribution to journalArticle

Chung, S. D. ; Lin, H. C. ; Tsai, M. C. ; Kao, L. T. ; Huang, C. Y. ; Chen, Kuan Chen. / Androgen deprivation therapy did not increase the risk of Alzheimer's and Parkinson's disease in patients with prostate cancer. In: Andrology. 2016 ; Vol. 4, No. 3. pp. 481-485.
@article{946c7301ca5c4a4abdec5c0515b638d3,
title = "Androgen deprivation therapy did not increase the risk of Alzheimer's and Parkinson's disease in patients with prostate cancer",
abstract = "Androgen deprivation therapy (ADT) has been the standard treatment for advanced prostate cancer for many decades. Although potential adverse effects of ADT have been reported, there are no empirical studies investigating the association between ADT and Alzheimer's disease. Therefore, this retrospective cohort study explored the relationship between the use of ADT and the subsequent risk of Alzheimer's disease in men with prostate cancer using a population-based database. We retrieved data from the {"}Taiwan Longitudinal Health Insurance Database 2000.{"} The study included 1335 patients with prostate cancer and 4005 age-matched comparison patients without prostate malignancy. We then individually tracked each patient (n = 5340) for a 5-year period to discriminate those who subsequently received a diagnosis of Alzheimer's disease. The Cox proportional hazard regression showed that the hazard ratio (HR) for Alzheimer's disease during the 5-year follow-up period for prostate cancer patients was 1.71 (95{\%} confidence interval (CI) = 0.90~3.25) over that of comparison patients. We further analyzed the hazard ratio for Alzheimer's disease and Parkinson's disease between prostate cancer patients who did and those who did not receive ADT, but we failed to observe a significant difference in the hazard ratio for both diseases during the 5-year follow-up period (adjusted HR = 1.76, 95{\%} CI = 0.55~5.62, and HR = 1.13, 95{\%} CI = 0.58~2.20, respectively). In conclusion, this study demonstrated that the use of androgen deprivation therapy in patients with prostate cancer was not associated with a higher risk of Alzheimer's and Parkinson's disease during the follow-up period.",
keywords = "Alzheimer's disease, Androgen deprivation therapy, Prostate cancer",
author = "Chung, {S. D.} and Lin, {H. C.} and Tsai, {M. C.} and Kao, {L. T.} and Huang, {C. Y.} and Chen, {Kuan Chen}",
year = "2016",
month = "5",
day = "1",
doi = "10.1111/andr.12187",
language = "English",
volume = "4",
pages = "481--485",
journal = "Andrology",
issn = "2047-2919",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "3",

}

TY - JOUR

T1 - Androgen deprivation therapy did not increase the risk of Alzheimer's and Parkinson's disease in patients with prostate cancer

AU - Chung, S. D.

AU - Lin, H. C.

AU - Tsai, M. C.

AU - Kao, L. T.

AU - Huang, C. Y.

AU - Chen, Kuan Chen

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Androgen deprivation therapy (ADT) has been the standard treatment for advanced prostate cancer for many decades. Although potential adverse effects of ADT have been reported, there are no empirical studies investigating the association between ADT and Alzheimer's disease. Therefore, this retrospective cohort study explored the relationship between the use of ADT and the subsequent risk of Alzheimer's disease in men with prostate cancer using a population-based database. We retrieved data from the "Taiwan Longitudinal Health Insurance Database 2000." The study included 1335 patients with prostate cancer and 4005 age-matched comparison patients without prostate malignancy. We then individually tracked each patient (n = 5340) for a 5-year period to discriminate those who subsequently received a diagnosis of Alzheimer's disease. The Cox proportional hazard regression showed that the hazard ratio (HR) for Alzheimer's disease during the 5-year follow-up period for prostate cancer patients was 1.71 (95% confidence interval (CI) = 0.90~3.25) over that of comparison patients. We further analyzed the hazard ratio for Alzheimer's disease and Parkinson's disease between prostate cancer patients who did and those who did not receive ADT, but we failed to observe a significant difference in the hazard ratio for both diseases during the 5-year follow-up period (adjusted HR = 1.76, 95% CI = 0.55~5.62, and HR = 1.13, 95% CI = 0.58~2.20, respectively). In conclusion, this study demonstrated that the use of androgen deprivation therapy in patients with prostate cancer was not associated with a higher risk of Alzheimer's and Parkinson's disease during the follow-up period.

AB - Androgen deprivation therapy (ADT) has been the standard treatment for advanced prostate cancer for many decades. Although potential adverse effects of ADT have been reported, there are no empirical studies investigating the association between ADT and Alzheimer's disease. Therefore, this retrospective cohort study explored the relationship between the use of ADT and the subsequent risk of Alzheimer's disease in men with prostate cancer using a population-based database. We retrieved data from the "Taiwan Longitudinal Health Insurance Database 2000." The study included 1335 patients with prostate cancer and 4005 age-matched comparison patients without prostate malignancy. We then individually tracked each patient (n = 5340) for a 5-year period to discriminate those who subsequently received a diagnosis of Alzheimer's disease. The Cox proportional hazard regression showed that the hazard ratio (HR) for Alzheimer's disease during the 5-year follow-up period for prostate cancer patients was 1.71 (95% confidence interval (CI) = 0.90~3.25) over that of comparison patients. We further analyzed the hazard ratio for Alzheimer's disease and Parkinson's disease between prostate cancer patients who did and those who did not receive ADT, but we failed to observe a significant difference in the hazard ratio for both diseases during the 5-year follow-up period (adjusted HR = 1.76, 95% CI = 0.55~5.62, and HR = 1.13, 95% CI = 0.58~2.20, respectively). In conclusion, this study demonstrated that the use of androgen deprivation therapy in patients with prostate cancer was not associated with a higher risk of Alzheimer's and Parkinson's disease during the follow-up period.

KW - Alzheimer's disease

KW - Androgen deprivation therapy

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84963763154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963763154&partnerID=8YFLogxK

U2 - 10.1111/andr.12187

DO - 10.1111/andr.12187

M3 - Article

VL - 4

SP - 481

EP - 485

JO - Andrology

JF - Andrology

SN - 2047-2919

IS - 3

ER -